This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

MX8899

Immune Pharmaceuticals Ltd.

Drug Names(s): Histamine Gel

Description: The active agent in the MX8899 gel is histamine dihydrochloride, which has been shown in preclinical work to reduce inflammation by preventing the production and release of oxygen free radicals and proinflamatory cytokines such as TNF-alpha and IL-1b, thereby reducing oxidative stress and inflammation.

Deal Structure: EpiCept and Immune
In November 2012, Immune Pharmaceuticals and EpiCept announced that they have entered into a definitive merger agreement. The combined company is to be named Immune Pharmaceuticals. In August 2013, Immune announced the completion of the merger of Immune Pharmaceuticals and EpiCept.


MX8899 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug